The nature of spontaneous recovery from mivacurium-induced neuromuscular block

C A Lien1, M R Belmont, A Abalos

  • 1Department of Anesthesiology, The New York Hospital-Cornell Medical Center, New York 10021, USA.

Abstract

Insights

Early recovery from mivacurium (0.3 mg/kg) predicts later recovery speed. This allows anesthesiologists to anticipate neuromuscular function recovery after mivacurium infusions, aiding in the decision for pharmacologic antagonism.

Area of Science:

  • Anesthesiology
  • Pharmacology
  • Neuromuscular Physiology

Background:

  • Mivacurium is a neuromuscular blocking agent used during anesthesia.
  • Predicting the duration of neuromuscular blockade is crucial for patient safety and timely extubation.
  • Spontaneous recovery from neuromuscular blocking agents can vary significantly between patients.

Purpose of the Study:

  • To test the hypothesis that early recovery from an initial dose of mivacurium predicts the time course of spontaneous recovery after an infusion.
  • To establish a correlation between early neuromuscular recovery and later recovery parameters.

Main Methods:

  • Thirty-eight male patients undergoing anesthesia received an initial dose of mivacurium (0.3 mg/kg).
  • Neuromuscular function was monitored using train-of-four (TOF) stimulation.
  • A mivacurium infusion was initiated upon initial recovery and discontinued as surgery concluded.
  • Recovery intervals were analyzed to correlate early recovery (5% T1) with later recovery (TOF ratios).

Main Results:

  • The time to 5% recovery of the first twitch (T1) after the initial mivacurium dose correlated with the time to achieve TOF ratios of 70% and 90%.
  • Recovery to a TOF of 90% after infusion discontinuation took approximately the same time as recovery to 5% T1 after the initial dose.
  • A strong correlation was found between early and late recovery phases for each patient.

Conclusions:

  • Early neuromuscular recovery after an initial dose of mivacurium is a reliable predictor of recovery speed following a mivacurium infusion.
  • This predictive relationship allows for better anticipation of neuromuscular function recovery and informs decisions regarding pharmacologic antagonism.
  • The findings support the ability to predict the need for antagonism well before the end of anesthesia.

Related Concept Videos

Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...